Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of T-cell large granular lymphocytic (T-LGL) leukemia~* Must have concurrent anemia or neutropenia~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 2 years~* Not pregnant~* Fertile patients must use effective contraception~* No other malignancy~* No active infection~PRIOR CONCURRENT THERAPY:~* No prior immunosuppressive treatment~* No previous treatment with methotrexate or fludarabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MTX followed by fludarabine (Type: EXPERIMENTAL): MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).